![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline... Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's product pipeline includes pepinemab (VX15), which targets Huntington's Disease (HD) and non-small cell lung cancer (NSCLC) and also neurodegenerative disorders; VX5 Autoimmune for the treatment of MS and potentially for other autoimmune disorder; and others. Show more
NEW DELHI, INDIA -- (Marketwire) -- 11/04/09 -- TheFortuneFinancial.com provides the highest level of independent research and investment strategies with the sole purpose of consistently...
Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announced that they will complete their merger shortly after 4:00PM ET today. The companies will...
By Peter Loftus Of DOW JONES NEWSWIRES Sales of embattled cholesterol drugs co-marketed by Merck & Co. (MRK) and Schering-Plough Corp. (SGP) could decline further after eagerly awaited...
Interim results of Phase IIa NEXT-I study presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough...
The Food and Drug Administration has turned away a new-drug application which would combine cholesterol treatments Zetia and Lipitor, saying additional data are needed. Lipitor is the world's...
Program Focus: Community Education and Mass Vaccination of Dogs in 10 Villages KENILWORTH, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced it has...
KENILWORTH, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet...
BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported two data presentations supporting response guided therapy with boceprevir combination therapy in...
KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE:SGP) announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the...
CHICAGO, Oct. 30 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for CSCO, SGP, BHP, COST, and AEO. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.05 | -28.6312849162 | 7.16 | 8.9 | 4.95 | 154833 | 7.98215126 | CS |
4 | -1.74 | -25.401459854 | 6.85 | 8.9 | 4.95 | 94201 | 7.47004839 | CS |
12 | -0.94 | -15.5371900826 | 6.05 | 8.9 | 4.82 | 48943 | 7.18660463 | CS |
26 | -3.78 | -42.5196850394 | 8.89 | 13.02 | 4.432 | 53625 | 8.78589651 | CS |
52 | -53.27 | -91.2470023981 | 58.38 | 64.89 | 4.432 | 239882 | 18.28670734 | CS |
156 | -509.39 | -99.0068027211 | 514.5 | 560.7 | 4.432 | 292825 | 171.35443605 | CS |
260 | -994.49 | -99.4887955182 | 999.6 | 2568.3 | 4.432 | 589989 | 691.68772113 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions